DOCSLIB.ORG

Kopia Pliku Product Device Suplement Cosmetic List for Internet Website Checked KRK 24.6.2020 Robocza Na 01.2021Poprawiony Fina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kopia Pliku Product Device Suplement Cosmetic List for Internet Website Checked KRK 24.6.2020 Robocza Na 01.2021Poprawiony Fina Nazwa handlowa Zarejestrowany produkt Substancja czynna Adempas Riociguat 0.5 mg tabletki powlekane Riociguat Adempas Riociguat 1 mg tabletki powlekane Riociguat Adempas Riociguat 1.5 mg tabletki powlekane Riociguat Adempas Riociguat 2 mg tabletki powlekane Riociguat Adempas Riociguat 2.5 mg tabletki powlekane Riociguat ADT Feed ADT FEED Afrin Oxymetazolini hydrochloridum, 0,5 mg/ml, spray do nosa, Oxymetazolini hydrochloridum rotwór Afrin ND Oxymetazolini hydrochloridum, 0,5 mg/ml, spray do nosa, Oxymetazolini hydrochloridum rotwór Afrin ND Glicerol Oxymetazolini hydrochloridum, 0,5 mg/ml, spray do nosa, Oxymetazolini hydrochloridum rotwór Afrin ND Mentol Oxymetazolini hydrochloridum, 0,5 mg/ml, spray do nosa, Oxymetazolini hydrochloridum rotwór spray do nosa Afrin Pure Sea Baby naturalna, rozcieńczona woda morska spray do nosa Afrin Pure Sea Higiena Nosa naturalna, rozcieńczona woda morska spray do nosa Afrin Pure Sea Udożnianie nosa naturalna, rozcieńczona woda morska Alcohol cleansing swab wacik nasączony alkoholem w saszetce, składowa Zestawu Betaferon Training Kit Aleve Naproxen Sodium 220 mg, tabletki powlekane Naproxen sodium Alka-Seltzer Acetylsalicylic acid-Sodium hydrogencarbonate-Citric acid, Acetylsalicylic acid; Citric acid; Sodium hydrogen tabletki musujące carbonate Androcur Cyproterone acetate (ANDROCUR THERA) 50 mg Tabletki Cyproterone acetate Angeliq Drospirenone-Estradiol (ANGELIQ 1/2) tabletki powlekane Drospirenone; Estradiol Aspirin Acetylsalicylic acid 0.5 g Tabletki Acetylsalicylic acid Aspirin C Acetylsalicylic acid-Ascorbic acid tabletki musujące Acetylsalicylic acid; Ascorbic acid Aspirin C Forte Acetylsalicylic acid-Ascorbic acid tabletki musujące Acetylsalicylic acid; Ascorbic acid Aspirin Cardio Acetylsalicylic acid 0,1 g tabletki powlekane Acetylsalicylic acid Aspirin Complex Hot Acetylsalicylic acid-Pseudoephedrine hydrochloride, granulki Acetylsalicylic acid; Pseudoephedrine Hydrochloride Aspirin Complex Zatoki Acetylsalicylic acid-Pseudoephedrine hydrochloride granulat Acetylsalicylic acid; Pseudoephedrine Hydrochloride musujacy Aspirin Effect Acetylsalicylic acid 500 mg Granulki Acetylsalicylic acid Aspirin Extra Acetylsalicylic acid-Caffeine tabletki Acetylsalicylic acid; Caffeine Aspirin mususjąca Acetylsalicylic acid 0.5 g tabletki musujące Acetylsalicylic acid Aspirin Pro Acetylsalicylic acid 500 mg Tabletki Acetylsalicylic acid Aspirin Pro Forte Acetylsalicylic acid 1000 mg Tabletki Acetylsalicylic acid Avanta Bottle Heat Maintainer (AVA 500 BTLH-L) Avanta Bottle Heat Maintainer (AVA 500 BTLH-M) Avanta Footswitch (AVA 500 FTC) Avanta Syringe Heat Maintainer (AVA 500 SYRH) Bepanthen Dexpanthenol 1600188 5.25 percent weight/volume Cream Dexpanthenol MAA Poland (Bepanthen) 50 mg/g Krem Bepanthen Baby Bepanthen Baby Woda Morska Bepanthen Derm krem Bepanthen Eye Bepanthen Plus Dexpanthenol-Chlorhexidine hydrochloride Krem Chlorhexidine hydrochloride; Dexpanthenol Bepanthen Sensiderm Daily Care Bepanthen Sensiderm Krem Berocca Performance (EFF) tabletki musujące Berocca Performance (FCT) tabletki powlekane Betacomfort Autowstrzykiwacz do produktu leczniczego Betaferon Betaconnect Autowstrzykiwacz do produktu leczniczego Betaferon Betaferon Interferon beta-1b (BETAFERON Combipack) 250 µg/1 ml Interferon beta-1b Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Betaject Comfort Autowstrzykiwacz do produktu leczniczego Betaferon Betaject Lite Autowstrzykiwacz do produktu leczniczego Betaferon BLF 100 lactoferrin, fructoligosacharides Bonefos Disodium clodronate (BONEFOS) 400 mg, kapsułki Disodium clodronate Breelib Canespor Bifonazole 1 % (W/W) Krem Bifonazole Canespor Onychoset Bifonazole-Urea maść Bifonazole; Urea Canesten Canesten, Clotrimazolum, 500 mg, kapsułki dopochwowe Clotrimazolum miękkie Canesten Canesten, Clotrimazolum, 500 mg, tabletki dopochwowe Clotrimazolum Centargo Injection System + składowe Certegra Certegra Workstation Informatiucs Panel and Modality Worklist (CWKS STARTER PKG) Ciprobay 500 Ciprofloxacin 500 mg, tabletki powlekane Ciprofloxacin HCl Claritine syrop Loratadinum Claritine tabletki Loratadinum Claritine Active tabletki o przedłużonym uwalnianiu Loratadinum+ Pseudoephedrini sulfas Claritine Allergy syrop Loratadinum Claritine Allergy tabletki Loratadinum Claritine Duo tabletki o przedłużonym uwalnianiu Loratadinum+ Pseudoephedrini sulfas Climara-50 Estradiol (CLIMARA 50) System transdermalny Estradiol Connectivity with >2 PACS Systems Connectivity with 2 PACS Systems CR/DR Procedures CT TRI-PAK Sterile Disposable Syringe (CTP-125-FLS) CT TRI-PAK Sterile Disposable Syringe (CTP-205-FLS) CT/IR Procedures CT/IR Procedures CT/IR Procedures CT/IR Procedures CT/IR Procedures CT/IR Procedures CT/IR Procedures Cyclo-Progynova Estradiol valerate-Norgestrel (CYCLO-PROGYNOVA 2/500) Estradiol valerate; Norgestrel tabletki powlekane Diane -35 Cyproterone acetate-Ethinylestradiol (DIANE, yellow) tabletki Cyproterone acetate; Ethinylestradiol powlekane Dicoflor drops Lactobacillus rhamnosus Dicoflor 3 kapsuki Lactobacillus rhamnosus Dicoflor 3 saszetki Lactobacillus rhamnosus Dicoflor 6 kapsułki Lactobacillus rhamnosus Dicoflor Elektrolity (poprzednia nazwa Floridral) Lactobacillus rhamnosus+mineral salts Dicoflor Junior Lactobacillus rhamnosus Dicoflor Odporność Lactobacillus rhamnosus, complex vit B, zinc Diprobase krem n/a Diprobase maść n/a Display Control Unit Sheath Disposable MRI Kit (SQK 65S) Disposable MRI Kit for 65/115 MR Injector System (SSQK Disposable MRI Kit with Check Valve (SQK 65VS, SQK 65VA) Distributed Architecture Dotagraf Dotagraf, 0,5 mmol/ml, roztwór do wstrzykiwań Gadoterate meglumine Dotagraf multidose Dotagraf multidose, 0,5 mmol/ml, roztwór do wstrzykiwań Gadoterate meglumine Dual Check-Valve Transfer Set for CT (CVTS) Dual Check-Valve Transfer Set for MR (MRTS) Elevit Pronatal Elevit tabletki powlekane Biotin; Calcium ascorbate dihydrate; Calcium hydrogen Enterprise license - data aggregation across sites Eylea Aflibercept (EYLEA) 40 mg/ml roztwór do wstrzykiwań (fiolka) Aflibercept Eylea Aflibercept (EYLEA) 40 mg/ml roztwór do wstrzykiwań Aflibercept (ampułkostrzykawka) Female Luer Transfer Set (FTS) Female-female adapter (FEA 50) Femoden Ethinylestradiol-Gestodene (FEMOVAN), tabletki powlekane Ethinylestradiol, Gestodene FL7 Interface (MIS PCS 301) Gadograf Gadobutrol (GADOVIST) 1 mmol/1 ml roztwór do Gadobutrol wstrzykiwań (fiolka) Gadograf Gadobutrol (GADOVIST) 1 mmol/1 ml roztwór do Gadobutrol wstrzykiwań (ampułkostrzykawka) Gadovist Gadobutrol (GADOVIST) 1 mmol/1 ml roztwór do Gadobutrol wstrzykiwań Gastrografin Meglumine amidotrizoate-Sodium amidotrizoate Meglumine amidotrizoate; Sodium amidotrizoate (GASTROGRAFIN with anise oil) roztwór doustny i doodbytniczy Glucobay 100 Acarbose 100 mg Tabletki Acarbose Glucobay 50 Acarbose 50 mg Tabletki Acarbose Gynodian Depot Estradiol valerate-Prasterone enantate (GYNODIAN Estradiol valerate; Prasterone enantate DEPOT), Roztwór do wstrzykiwań Hand Controller Sheath High Pressure Contrast Injection Line Iberogast Płyn doustny produkt złożony ISI2 Jaydess Levonorgestrel (JAYDESS) 13.5 mg system terapeutyczny Levonorgestrel domaciczny Jeanine Dienogest-Ethinylestradiol (VALETTE without gelatine) Dienogest; Ethinylestradiol tabletki powlekane Jivi 1 000 j.m. Antihemophilic Factor Pegol (JIVI) 1000 IU proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Damoctocog Alfa Pegol Jivi 2 000 j.m. Antihemophilic Factor Pegol (JIVI) 2000 IU proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Damoctocog Alfa Pegol Antihemophilic Factor Pegol (JIVI) 250 IU proszek i Jivi 250 j.m. rozpuszczalnik do sporządzania roztworu do wstrzykiwań Damoctocog Alfa Pegol Jivi 3 000 j.m. Antihemophilic Factor Pegol (JIVI) 3000 IU proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Damoctocog Alfa Pegol Jivi 500 j.m. Antihemophilic Factor Pegol (JIVI) 500 IU Pproszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań Damoctocog Alfa Pegol Kinzalkomb Telmisartan-HCT 40+12.5 Tabletki Hydrochlorothiazide; Telmisartan Kinzalkomb Telmisartan-HCT 80+12.5 Tabletki Hydrochlorothiazide; Telmisartan Kinzalkomb Telmisartan-HCT 80+25 Tabletki Hydrochlorothiazide; Telmisartan Kinzalmono Telmisartan 20 mg Tabletki Telmisartan Kinzalmono Telmisartan 40 mg Tabletki Telmisartan Kinzalmono Telmisartan 80 mg Tabletki Telmisartan Klimonorm Estradiol valerate-Levonorgestrel (KLIMONORM), tabletki Estradiol valerate; Levonorgestrel powlekane Kogenate Bayer Antihemophilic Factor (Recombinant) 1000 IUProszek i Octocog Alfa BAY 142222 rozpuszczalnik do sporządzenia roztworu do wstrzykiwań Kogenate Bayer Antihemophilic Factor (Recombinant) 2000 IU Proszek i Octocog Alfa BAY 142222 rozpuszczalnik do sporządzenia roztworu do wstrzykiwań Kogenate Bayer Antihemophilic Factor (Recombinant) 250 IU Proszek i Octocog Alfa BAY 142222 rozpuszczalnik do sporządzenia roztworu do wstrzykiwań Kogenate Bayer Antihemophilic Factor (Recombinant) 3000 IU Proszek i Octocog Alfa BAY 142222 rozpuszczalnik do sporządzenia roztworu do wstrzykiwań Kogenate Bayer Antihemophilic Factor (Recombinant) 500 IU Proszek i Octocog Alfa BAY 142222 rozpuszczalnik do sporządzenia roztworu do wstrzykiwań Antihemophilic Factor (Recombinant) proszek i Octocog Alfa Kovaltry 1000 j.m. rozpuszczalnik do sporządzania roztworu do wstrzykiwań Antihemophilic Factor (Recombinant) proszek i Octocog Alfa Kovaltry 2000 j.m. rozpuszczalnik do sporządzania roztworu do wstrzykiwań Antihemophilic Factor (Recombinant) proszek i Octocog Alfa Kovaltry
Load more

Recommended publications
  • Androgen Excess in Breast Cancer Development: Implications for Prevention and Treatment
    26 2 Endocrine-Related G Secreto et al. Androgen excess in breast 26:2 R81–R94 Cancer cancer development REVIEW Androgen excess in breast cancer development: implications for prevention and treatment Giorgio Secreto1, Alessandro Girombelli2 and Vittorio Krogh1 1Epidemiology and Prevention Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milano, Italy 2Anesthesia and Critical Care Medicine, ASST – Grande Ospedale Metropolitano Niguarda, Milano, Italy Correspondence should be addressed to G Secreto: [email protected] Abstract The aim of this review is to highlight the pivotal role of androgen excess in the Key Words development of breast cancer. Available evidence suggests that testosterone f breast cancer controls breast epithelial growth through a balanced interaction between its two f ER-positive active metabolites: cell proliferation is promoted by estradiol while it is inhibited by f ER-negative dihydrotestosterone. A chronic overproduction of testosterone (e.g. ovarian stromal f androgen/estrogen balance hyperplasia) results in an increased estrogen production and cell proliferation that f androgen excess are no longer counterbalanced by dihydrotestosterone. This shift in the androgen/ f testosterone estrogen balance partakes in the genesis of ER-positive tumors. The mammary gland f estradiol is a modified apocrine gland, a fact rarely considered in breast carcinogenesis. When f dihydrotestosterone stimulated by androgens, apocrine cells synthesize epidermal growth factor (EGF) that triggers the ErbB family receptors. These include the EGF receptor and the human epithelial growth factor 2, both well known for stimulating cellular proliferation. As a result, an excessive production of androgens is capable of directly stimulating growth in apocrine and apocrine-like tumors, a subset of ER-negative/AR-positive tumors.
    [Show full text]
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • Estradiol (E2), Estriol (E3), Ethinylestradiol (EE2), Testosterone (TEST), Androstenedione (AND), and Progesterone
    UNIVERSITY OF CINCINNATI Date: 13-Aug-2010 I, Ruth Marfil Vega , hereby submit this original work as part of the requirements for the degree of: Doctor of Philosophy in Environmental Science It is entitled: Abiotic Transformation of Estrogens in Wastewater Student Signature: Ruth Marfil Vega This work and its defense approved by: Committee Chair: Makram Suidan, PhD Makram Suidan, PhD George Sorial, PhD George Sorial, PhD Margaret Kupferle, PhD, PE Margaret Kupferle, PhD, PE Marc Mills, PhD Marc Mills, PhD 11/8/2010 1,041 Abiotic Transformation of Estrogens in Wastewater A Dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy In the School of Energy, Environmental, Biological and Medical Engineering By Ruth Marfil-Vega B.S. Chemistry, University of Valladolid, Spain, 2001 Committee Chair: Makram T. Suidan, Ph.D. ABSTRACT The fate of seven steroids: estrone (E1), estradiol (E2), estriol (E3), ethinylestradiol (EE2), testosterone (TEST), androstenedione (AND), and progesterone (PROG), in the presence of synthetic wastewater was studied in order to establish the role abiotic processes play in the elimination of these chemicals from the environment. Comprehension of these mechanisms will foster the optimization of the existing wastewater treatment technologies and the development of sustainable alternatives. Distinctive behavior was encountered for the target compounds in accordance with their chemical structure, hence, different physico-chemical properties and reactivity. Estrogenic compounds, comprising E1, E2, E3 and EE2, were found to undergo a catalytic transformation when contacted with a model vegetable material present in the synthetic wastewater.
    [Show full text]
  • Loette (Levonorgestrel and Ethinylestradiol) Tablets
    AUSTRALIAN PRODUCT INFORMATION - LOETTE (LEVONORGESTREL AND ETHINYLESTRADIOL) TABLETS 1. NAME OF THE MEDICINE Levonorgestrel and Ethinylestradiol 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pink tablet contains levonorgestrel 100 g and ethinylestradiol 20 g. Each white tablet contains no active ingredients. Excipients with known effect Lactose monohydrate For the full list of excipients, see section 6.1, List of Excipients. 3. PHARMACEUTICAL FORM Tablet, film coated. Pink tablet: Round, pink, biconvex, film coated tablets with "W" debossed on one side and "912" debossed on the other side. White tablet: White film-coated round tablet with convex faces. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications LOETTE is indicated for: The prevention of pregnancy. The treatment of moderate acne vulgaris not controlled with topical preparations in post-menarchal, pre-menopausal women who accept contraception. Version:pfploett11219 Supersedes: pfploett11018 Page 1 of 29 4.2 Dose and method of administration How to Take LOETTE Each package of LOETTE contains 21 active pink tablets and 7 white inactive tablets. To achieve maximum contraceptive effectiveness, LOETTE must be administered as directed and at the same time every day, at intervals not exceeding 24 hours. The recommended dose for the prevention of pregnancy and the treatment of acne is the same. Where poor compliance is a concern, an oral contraceptive with higher levels of estrogens and progestogens should be considered (see section 5.1, Pharmacodynamic Properties, Clinical Trials). How to Start LOETTE No Preceding Hormonal contraceptive Use (in the Past Month) On the first day of the menstrual cycle, i.e. the first day of bleeding, the woman is instructed to take a pink active tablet corresponding to that day of the week from the pink shaded section of the LOETTE pack.
    [Show full text]
  • Effects of Aminoglutethimide on A5-Androstenediol Metabolism in Postmenopausal Women with Breast Cancer1
    [CANCER RESEARCH 42, 4797-4800, November 1982] 0008-5472/82/0042-0000802.00 Effects of Aminoglutethimide on A5-Androstenediol Metabolism in Postmenopausal Women with Breast Cancer1 Charles E. Bird,2 Valerie Masters, Ernest E. Sterns, and Albert F. Clark Departments of Medicine [C. E. B., V. M.], Surgery [E. E. S.J, and Biochemistry [A. F. C.], Queen s University and Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7 ABSTRACT women. More recently, we (8) and others (18) reported that the production of A5-androstene-3/8,17/8-diol in normal post- A5-Androstene-3/8,1 7/S-diol has potential estrogenic activity menopausal women is approximately 500 to 700 fig/24 hr. because it is known to bind to receptors and translocate to the AG, in combination with hydrocortisone, has been utilized to nucleus of certain estrogen target tissues. Its role in the biology inhibit estrogen production in patients with breast cancer (21 ). of breast cancer is unclear. Aminoglutethimide plus hydrocor This form of therapy has been termed "medical adrenalec tisone ("medical adrenalectomy") has been used to treat post- tomy," and studies suggest that it is as effective as surgical menopausal women with metastatic breast cancer. adrenalectomy. The hydrocortisone shuts off the basal adre- We studied A5-androstene-3/3,17/?-diol metabolism in post- nocortical production of estrogen precursors; AG not only menopausal women with breast cancer before and during slows down steroid biosynthesis at an early step but also aminoglutethimide-plus-hydrocortisone therapy, utilizing the specifically inhibits the aromatization of A4-androstenedione to constant infusion technique.
    [Show full text]
  • Effects of 17Α-Ethinylestradiol on Sexual Development of the Amphipod Hyalella Azteca
    ARTICLE IN PRESS Ecotoxicology and Environmental Safety ] (]]]]) ]]]–]]] Effects of 17a-ethinylestradiol on sexual development of the amphipod Hyalella azteca Gert F. Vandenbergh,a Dominique Adriaens,b Tim Verslycke,a,* and Colin R. Janssena a Laboratory of Environmental Toxicology and Aquatic Ecology, Ghent University, J. Pateaustraat 22, 9000 Ghent, Belgium b Vertebrate Morphology, Ghent University, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium Received 31 July 2001; accepted 7 March 2002 Abstract The effects of the synthetic estrogen 17a-ethinylestradiol (EE) on sexual development of the freshwater amphipod Hyalella azteca was investigated. Organisms were exposed in a multigeneration experiment to EE concentrations ranging from 0.1 to 10 mg/L and the development of both external and internal sexual characteristics were studied. Second-generation male H. azteca exposed from gametogenesis until adulthood to 0.1 and 0.32 mg EE/L developed significantly smaller second gnathopods. The sex ratio of the populations exposed to EE for more than two generations tended, although not statistically significantly, to be in favor of females. Histological aberrations of the reproductive tract, i.e., indications of hermaphroditism, disturbed maturation of the germ cells, and disturbed spermatogenesis, of post-F1-generation males were observed in all EE exposures. These findings provide evidence that sexual development of H. azteca is affected by exposure to sublethal concentrations of EE. r 2002 Elsevier Science (USA). All rights reserved. Keywords: Endocrine disruption; Invertebrates; Crustaceans; Hyalella azteca; Sexual development; Histology 1. Introduction not fully understood (Fairs et al., 1989; Jeng et al., 1978; Novak et al., 1990). Sexual differentiation in malacos- There has been increasing concern about the potential tracan crustaceans, such as amphipods, is regulated by of anthropogenic chemicals to disrupt the regulation the androgenic gland (AG).
    [Show full text]
  • TWYNSTA (Telmisartan/Amlodipine) Tablets Are Indicated for the Treatment of Hypertension, Alone Or with Other Antihypertensive Agents
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use • Tablets: 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg (3) TWYNSTA safely and effectively. See full prescribing information for TWYNSTA. -------------------------------CONTRAINDICATIONS------------------------------ • None TWYNSTA® (telmisartan/amlodipine) Tablets Initial U.S. Approval: 2009 -----------------------WARNINGS AND PRECAUTIONS------------------------ • Avoid fetal or neonatal exposure (5.1) WARNING: AVOID USE IN PREGNANCY • Hypotension: Correct any volume or salt depletion before initiating See full prescribing information for complete boxed warning. therapy. Observe for signs and symptoms of hypotension. (5.2) When pregnancy is detected, discontinue TWYNSTA as soon as possible. • Titrate slowly in patients with hepatic (5.4) or severe renal impairment Drugs that act directly on the renin-angiotensin system can cause injury (5.5) and even death to the developing fetus (5.1) • Heart failure: Monitor for worsening (5.8) • Avoid concomitant use of an ACE inhibitor and angiotensin receptor ----------------------------INDICATIONS AND USAGE--------------------------- blocker (5.6) • TWYNSTA is an angiotensin II receptor blocker (ARB) and a • Myocardial infarction: Uncommonly, initiating a CCB in patients with dihydropyridine calcium channel blocker (DHP-CCB) combination severe obstructive coronary artery disease may precipitate myocardial product indicated for the treatment
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis
    IMPORTANCE OF HEPATIC TRANSPORTERS, INCLUDING BASOLATERAL EFFLUX PROTEINS, IN DRUG DISPOSITION: IMPACT OF PHOSPHOLIPIDOSIS AND NON-ALCOHOLIC STEATOHEPATITIS Brian C. Ferslew A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmaceutical Sciences in the UNC Eshelman School of Pharmacy Chapel Hill 2014 Approved by: Dhiren Thakker Mary F. Paine A. Sidney Barritt Kim L.R. Brouwer Jo Ellen Rodgers Wei Jia ©2014 Brian C. Ferslew ALL RIGHTS RESERVED ii ABSTRACT Brian C. Ferslew: Importance of Hepatic Transporters, Including Basolateral Efflux Proteins, in Drug Disposition: Impact of Phospholipidosis and Non-Alcoholic Steatohepatitis (Under the direction of Kim L.R. Brouwer) The objective of this dissertation project was to develop preclinical and clinical tools to assess the impact of liver pathology on transporter-mediated systemic and hepatic exposure to medications. A translational approach utilizing established pre-clinical hepatic transport systems, mathematical modeling, and a pivotal in vivo human study was employed. A novel application of rat sandwich-cultured hepatocytes (SCH) was developed to evaluate the impact of drug-induced phospholipidosis on the vectorial transport of probe substrates for hepatic basolateral and canalicular transport proteins. Results indicated that rat SCH treated with prototypical hepatic phospholipidosis inducers are a sensitive and selective model for drug-induced phospholipidosis; both organic anion transporting polypeptide-mediated uptake and bile salt export pump-mediated biliary excretion were reduced after the onset of phospholipidosis. Enalapril currently is being investigated for its anti-fibrotic effects in the treatment of patients with non-alcoholic steatohepatitis (NASH).
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Telmisartan Teva, INN-Telmisartan
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Telmisartan Teva 20 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg telmisartan Excipients: Each tablet contains 21.4 mg sorbitol (E420) For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet White to off white, oval shaped tablet; one side of the tablet is debossed with the number "93". The other side of the tablet is debossed with the number "7458". 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of essential hypertension in adults. 4.2 Posology and method of administration The usually effective dose is 40 mg once daily. Some patients may already benefit at a daily dose of 20 mg. In cases where the target blood pressure is not achieved, the dose of telmisartan can be increased to a maximum of 80 mg once daily. Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan. When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment (see section 5.1). Telmisartan may be taken with or without food. Renal impairment No posology adjustment is required for patients with mild to moderate renal impairment. Limited experience is available in patients with severe renal impairment or haemodialysis. A lower starting dose of 20 mg is recommended in these patients (see section 4.4). Hepatic impairment In patients with mild to moderate hepatic impairment, the posology should not exceed 40 mg once daily (see section 4.4).
    [Show full text]